228 related articles for article (PubMed ID: 32098624)
21. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
[TBL] [Abstract][Full Text] [Related]
22. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone use and risk of bladder cancer: population based cohort study.
Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
[TBL] [Abstract][Full Text] [Related]
24. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
Chang SS; Hu HY
BMC Cancer; 2013 Sep; 13():420. PubMed ID: 24041200
[TBL] [Abstract][Full Text] [Related]
25. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Hickson RP; Cole AL; Dusetzina SB
J Manag Care Spec Pharm; 2019 Jan; 25(1):72-79. PubMed ID: 30589625
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinediones: the Forgotten Diabetes Medications.
Lebovitz HE
Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
[TBL] [Abstract][Full Text] [Related]
30. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Colhoun HM; Livingstone SJ; Looker HC; Morris AD; Wild SH; Lindsay RS; Reed C; Donnan PT; Guthrie B; Leese GP; McKnight J; Pearson DW; Pearson E; Petrie JR; Philip S; Sattar N; Sullivan FM; McKeigue P;
Diabetologia; 2012 Nov; 55(11):2929-37. PubMed ID: 22945303
[TBL] [Abstract][Full Text] [Related]
31. Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study.
Lee TTL; Hui JMH; Lee YHA; Satti DI; Shum YKL; Kiu PTH; Wai AKC; Liu T; Wong WT; Chan JSK; Cheung BMY; Wong ICK; Cheng SH; Tse G
J Am Heart Assoc; 2022 Sep; 11(18):e026289. PubMed ID: 36102222
[TBL] [Abstract][Full Text] [Related]
32. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
33. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract][Full Text] [Related]
36. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Loke YK; Singh S; Furberg CD
CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
[TBL] [Abstract][Full Text] [Related]
37. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
38. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
39. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
40. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]